echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > CD73 monoclonal antibody!

    CD73 monoclonal antibody!

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ArticleMedicine Guanlan

    On October 15th, Jax Pharmaceuticals announced that the company's self-developed CD73 monoclonal antibody JAB-BX102 clinical trial application has been approved by the FDA, and Phase 1/2a clinical trials will be carried out in the United States


    CD73 is a rate-limiting enzyme that catalyzes the conversion of adenosine monophosphate (AMP) to adenosine.


    JAB-BX102 is a CD73 monoclonal antibody independently developed by Jacos Pharmaceuticals


    (The original text has been deleted)

    Reference materials:

    [1] Jacosi CD73 monoclonal antibody JAB-BX102 obtained new drug clinical trial approval in the United States.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.